G2GBIO
G2GBIO is a clinical-stage Korean biotech (KOSDAQ-listed) that develops long-acting injectable microsphere formulations through its proprietary InnoLAMP platform, licensing the technology and co-developing pipeline assets with global pharmaceutical partners including Samsung Bioepis and Boehringer Ingelheim.
- Company typePublic
- Founded2017
- HeadquartersCheongju, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What G2GBIO does
G2GBIO (지투지바이오 / Good to the Globe Biotech Company) is a clinical-stage Korean biotechnology firm founded in March 2017 by CEO Heeyong Lee, a 27+ year veteran of sustained-release drug delivery research from Peptron. The company is headquartered in Cheongju (Osong BioValley), South Korea, with a Seoul business development office and a GMP manufacturing facility also located in Cheongju. Listed on KOSDAQ in August 2025 at an estimated market capitalization of approximately 3.1 trillion KRW, G2GBIO is loss-making and pre-revenue, with cumulative sales of only ~200 million KRW against cumulative operating losses of ~9.2 billion KRW through Q3 2024.
The company's core technology is the proprietary InnoLAMP (Innovative Long-Acting Microsphere Platform) — a biodegradable PLGA microsphere drug delivery system that achieves drug loading above 60% for small molecules and above 50% for peptides, suppresses initial burst release, and enables sustained drug release from one week to over six months. InnoLAMP is paired with proprietary manufacturing methods including membrane emulsification and continuous solvent removal, supporting batch production of 30-60kg and a planned second GMP plant targeting ~7 million semaglutide patient-treatments per year by 2027. An extension platform, InteLAMP, applies the same microsphere technology to local-acting anticancer drug delivery within tumor tissue. The pipeline spans GB-5001 (donepezil, Alzheimer's), GB-5112 (rivastigmine), GB-6002 (ropivacaine, post-operative pain), GB-7001 (semaglutide, obesity/diabetes), GB-5021/5023 (brexpiprazole, schizophrenia), and additional assets across hepatitis B, prostate cancer, osteoarthritis, androgenetic alopecia, and veterinary applications.
G2GBIO operates a B2B enterprise model centered on technology licensing and co-development with global pharmaceutical companies, complemented by CDO/CDMO service contracts. Revenue is generated through upfront payments, development milestones, royalties on net sales, and service fees. Core partners include Samsung Bioepis (flagship licensing deal for semaglutide-based obesity treatments, March 2026), Boehringer Ingelheim (two peptide formulation contracts in 2025), Korea Pharma and Humedix (GB-5001 domestic commercialization), HanWha Pharma (GH-001 hepatitis B), and a Master Service Agreement with a global top-20 pharma company. The company retains global manufacturing rights in its licensing deals and supplies finished products to marketing partners. As of early 2026, no licensing payments or CDMO sales had been recognized despite multiple signed agreements.
G2GBIO firmographics
Firmographics- Name
- G2GBIO
- Legal name
- 주식회사 지투지바이오
- Website
- https://g2gbio.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- G2GBIO is a clinical-stage Korean biotech (KOSDAQ-listed) that develops long-acting injectable microsphere formulations through its proprietary InnoLAMP platform, licensing the technology and co-developing pipeline assets with global pharmaceutical partners including Samsung Bioepis and Boehringer Ingelheim.
- Ownership category
- akta.pro rank
G2GBIO industry classification
Industry- Product category
- Long-acting injectable drug delivery
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where G2GBIO is headquartered
LocationHeadquarters
- HQ city
- Cheongju
- HQ country
- South Korea
- HQ region
- Asia
Offices3 records
Markets served
G2GBIO business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Infrastructure, Personnel, Operations, Supply Chain
Revenue model
- Technology Licensing and Transfer: G2GBIO licenses its InnoLAMP platform technology and pipeline assets to global pharmaceutical companies in exchange for upfront payments, milestone payments, and ongoing royalties on net sales. Key deals include Samsung Bioepis (semaglutide, two assets) and ongoing negotiations with multiple global pharma companies. The company receives technology transfer fees, development milestones, and royalty payments upon commercialization.
- CDO/CDMO Services: Contract Development Organization (CDO) and Contract Development and Manufacturing Organization (CDMO) services utilizing the InnoLAMP microsphere platform. G2GBIO provides formulation development, scale-up research, and GMP manufacturing of microsphere injectables for partner companies on a project fee basis. A Master Service Agreement with a global top-20 pharma company is in place, with project-based orders expected to generate revenue.
- Product Sales (Future): Once pipeline products complete clinical development and receive regulatory approval, G2GBIO plans to commercialize through manufacturing and supply agreements with distribution partners. The company retains global manufacturing rights and supplies finished products to marketing partners.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
G2GBIO product offering
Product offeringCore offering
G2GBIO is a clinical-stage biotechnology company that develops and licenses proprietary long-acting injectable drug delivery platforms (InnoLAMP and InteLAMP) built on biodegradable polymer microsphere technology, together with a pipeline of sustained-release injectable pharmaceutical candidates spanning Alzheimer's, obesity/diabetes, post-operative pain, schizophrenia, hepatitis B, and other therapeutic areas. The company monetizes through technology licensing and co-development agreements with global pharmaceutical partners, CDO/CDMO service contracts, and — once approved — manufacturing supply to marketing partners.
Product overview
G2GBIO is a clinical-stage biotech company specializing in long-acting injectable drug delivery platforms. The company's core technology is the InnoLAMP (Innovative Long-Acting Microsphere Platform) for developing sustained-release microsphere injectables that maintain drug efficacy from one week to over six months. The second platform, InteLAMP, extends InnoLAMP for local-acting anticancer treatments. The product portfolio includes pipeline candidates spanning multiple therapeutic areas: GB-5001/GB-5001A (donepezil for Alzheimer's disease), GB-5112 (rivastigmine), GB-6002 (ropivacaine for post-operative pain), GB-7001 (semaglutide for diabetes/obesity), GB-5021/GB-5023 (brexpiprazole for schizophrenia), GB-5313 (osteoarthritis), GB-7101/GB-7103 (prostate cancer), GB-6201/GB-6203 (androgenetic alopecia), GH-001 (hepatitis B), and veterinary products GB-2001 and GB-2006. The company offers CDO/CDMO services leveraging its GMP facilities.
Differentiator
Problem solved
Functional benefit
Brands
- InnoLAMP: Proprietary Innovative Long-Acting MicroParticle platform technology for sustained-release drug delivery
- InteLAMP
Products and services
- InnoLAMP (Innovative Long-Acting Microsphere Platform)
Quantifiable outcome
- GB-5001 (donepezil): >98 days of PK activity demonstrated in clinical studies; 56-day sustained release for 1-month formulation, 112-day for 3-month formulation of brexpiprazole
- +5 more outcomes
Companies that use G2GBIO
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles5 records
G2GBIO technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
G2GBIO partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- Samsung Bioepis Co. Ltd. and Epis NexLabcoreSamsung Bioepis (a subsidiary of Samsung Epis Holdings) and Epis NexLab signed a joint research and license agreement with G2GBIO to develop long-acting obesity treatments using G2GBIO's microsphere technology. Samsung Bioepis obtained exclusive development and commercialization rights for two assets including a long-acting semaglutide-based obesity drug candidate, with options for additional assets. Samsung Epis Holdings invested 20 billion KRW ($13.35M) in convertible bonds issued by G2GBIO to strengthen the strategic partnership. G2GBIO retains global manufacturing rights.
- NovaCellminorG2GBIO and NovaCell signed an MOU for joint development of next-generation biodegradable microsphere-based peptide immunotherapy. The collaboration combines NovaCell's PEPTIROID immune-modulating peptide technology with G2GBIO's InnoLAMP and InteLAMP platforms to develop sustained-release injectable formulations for chronic inflammatory and autoimmune diseases including atopic dermatitis, rheumatoid arthritis, ulcerative colitis, and psoriasis.
- European Global Pharmaceutical Company (undisclosed)minorG2GBIO signed a research collaboration agreement with a European global pharmaceutical company in September 2025 for sustained-release injectable development using InnoLAMP technology. G2GBIO provides prototype formulations for preclinical PK/PD evaluation; the partner conducts animal testing and evaluation, with an exclusive option to license the developed formulation for commercialization.
- Ministry of Trade, Industry and Energy / Korea Materials & Components Technology Evaluation InstituteminorG2GBIO selected as a recipient of the Ministry of Trade, Industry and Energy's 2025 Materials and Components Technology Development Project. Awarded 2.5 billion KRW over 2.5 years for development of a 1-month sustained-release immunosuppressant injection for organ transplant patients using InnoLAMP technology.
- Boehringer IngelheimcoreBoehringer Ingelheim (Germany) signed a formulation development contract with G2GBIO for long-acting injectable peptide formulations using the InnoLAMP platform. A second additional formulation development contract was signed in July 2025. Boehringer Ingelheim provides proprietary peptide drugs; G2GBIO develops sustained-release microsphere formulations. Both contracts are part of ongoing strategic collaboration.
- Global Top-20 Pharmaceutical Company (undisclosed)coreG2GBIO signed a Master Service Agreement (MSA) with a global pharmaceutical company ranked in the top 20 by market capitalization for microsphere sustained release technology services. G2GBIO provides CDO (contract development organization) and CDMO services from formulation development through commercial manufacturing. The partner conducted GMP facility inspections in October 2024 as part of technology transfer evaluation. Project-specific contracts and CDO/CDMO revenue expected to begin in 2024+.
- Korea Pharma and HumedixcoreG2GBIO entered a joint development agreement with Korea Pharma and Humedix for donepezil long-acting injectable (GB-5001) for Alzheimer's disease. G2GBIO applies InnoLAMP technology for formulation development and manufacturing; Korea Pharma and Humedix conduct clinical trials, regulatory filing, and domestic sales. Partners pay milestone payments and royalties upon commercialization, and retain domestic rights.
- BC World PharmaminorG2GBIO signed a manufacturing cooperation agreement with BC World Pharma to leverage BC World Pharma's production infrastructure for InnoLAMP-based sustained-release injectable manufacturing. BC World Pharma's Yeoju facility (optimized for export to advanced markets) produces G2GBIO products. The agreement adds production capacity to accelerate pipeline development.
- Keyfron Bio (BiotoxTech subsidiary)minorG2GBIO and Keyfron Bio (a subsidiary of BiotoxTech) entered a joint development agreement for veterinary medicines. Keyfron Bio is responsible for clinical development of GB-2006 (animal post-operative pain treatment) and GB-2001 (animal castration). G2GBIO supplies formulation and manufacturing. BiotoxTech reportedly achieved ~13x return on its 1 billion KRW investment in G2GBIO.
- HanWha PharmacoreG2GBIO and HanWha Pharma signed a joint development agreement for a 3-month sustained-release hepatitis B antiviral injection (GH-001) using entecavir. G2GBIO handles formulation development and manufacturing; HanWha Pharma conducts clinical trials, regulatory approval, and sales, with rights to overseas markets.
Scale indicators8 records
Recent moves8 records
Expansion highlights8 records
G2GBIO competitors and assessment
Company assessmentDirect peers
- Peptron: Korean sustained-release peptide delivery company specializing in long-acting injectable microsphere formulations; G2GBIO's CEO Lee Hee-yong and Head of R&D Eunyoung Seol both previously led sustained-release programs at Peptron, making it the most directly comparable peer in technology and heritage.
- Camurus: Swedish specialty pharma company developing long-acting injectable depot formulations using its proprietary FluidCrystal technology; directly comparable to G2GBIO's InnoLAMP platform in targeting the same long-acting injectable market with similar drug delivery economics.
Broad incumbents
- Evonik Industries (Health Care): Global specialty chemicals company with a major pharmaceutical CDMO business including biodegradable PLGA polymers and injectable formulation services; a competitor/partner in the microsphere CDMO space and comparable as a scaled drug-delivery manufacturing platform.
- Pacira BioSciences: US-listed specialty pharma commercializing EXPAREL, a long-acting bupivacaine injectable for post-operative pain; comparable to G2GBIO's GB-6002 (long-acting ropivacaine) and represents a successful commercial template for sustained-release injectable platforms in the pain management space.
- Luye Pharma Group: China-headquartered specialty pharma with long-acting injectable CNS portfolio (e.g., Risperdal Consta biosimilar, ER liposomal platforms); comparable in the long-acting injectable antipsychotic/schizophrenia space where G2GBIO's GB-5021/GB-5023 competes.
- Halozyme Therapeutics: US biotech commercializing the ENHANZE drug delivery platform (recombinant human hyaluronidase) for subcutaneous large-volume injectables; comparable business model of licensing proprietary delivery technology to global pharma for co-development and royalty revenue.
- Novartis - Signifor LAR franchise: Owner of Signifor LAR (pasireotide long-acting release), used as another key commercial benchmark for InnoLAMP's high peptide drug-loading claims; reference standard for long-acting peptide microsphere technology.
Others
- Johnson & Johnson (Janssen) - Risperdal Consta franchise: Owner of Risperdal Consta, the long-acting injectable risperidone microsphere product used as a key commercial benchmark for G2GBIO's InnoLAMP drug-loading and PK performance claims.
- Ashland (Pharmaceutical Specialties): Global specialty chemicals company providing pharmaceutical excipients, polymers, and drug delivery enabling technologies for sustained-release injectables; comparable as an enabling infrastructure participant in the long-acting injectable CDMO ecosystem.
Regional players
- Samyang Biopharm: Korean specialty pharma with biodegradable polymer drug delivery expertise and long-acting injectable development capabilities; comparable Korean peer in sustained-release microsphere technology and therapeutic positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
G2GBIO social profiles
Digital presenceG2GBIO financial estimates
Financial estimateRevenue estimate
Valuation estimate
G2GBIO leadership team
Management profileNumber of profiles
Profiles3 records
G2GBIO funding detail
Funding detailFunding overview
Funding rounds8 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
G2GBIO M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about G2GBIO
What does G2GBIO do?
G2GBIO is a clinical-stage biotechnology company that develops and licenses proprietary long-acting injectable drug delivery platforms (InnoLAMP and InteLAMP) built on biodegradable polymer microsphere technology, together with a pipeline of sustained-release injectable pharmaceutical candidates spanning Alzheimer's, obesity/diabetes, post-operative pain, schizophrenia, hepatitis B, and other therapeutic areas. The company monetizes through technology licensing and co-development agreements with global pharmaceutical partners, CDO/CDMO service contracts, and — once approved — manufacturing supply to marketing partners.
Is G2GBIO a public or private company?
G2GBIO is a public company. It is classified as public and is currently operating.
When was G2GBIO founded?
G2GBIO was founded in 2017. It employs 11 to 50 people.
Where is G2GBIO based?
G2GBIO is headquartered in Cheongju, South Korea, in the Asia region.
How does G2GBIO make money?
Three revenue lines are on record. Technology Licensing and Transfer is the primary driver. The others are CDO/CDMO Services and product Sales (Future).
Who are G2GBIO's main competitors?
Direct peers on record are Peptron and Camurus. Broad incumbents are Evonik Industries (Health Care), Pacira BioSciences, Luye Pharma Group, Halozyme Therapeutics and Novartis - Signifor LAR franchise. Others are Johnson & Johnson (Janssen) - Risperdal Consta franchise and Ashland (Pharmaceutical Specialties). Samyang Biopharm is listed as a regional player.
Does G2GBIO have an API?
No public API is recorded for G2GBIO.
What industry is G2GBIO in?
G2GBIO's product category is Long-acting injectable drug delivery. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.